Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 10/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.43 |
| ▸ | SLC1A5 | Q15758 | 4/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2397235 | 1.00 | KIF11 (0.43) | KIF11KLKB1SLC1A5IDO1DNMT1 | |
| SCHEMBL12264339 | 0.88 | L3MBTL1 (0.38) | KIF11 | |
| SCHEMBL11860380 | 0.83 | KIF11 (0.49) | KIF11KLKB1SLC1A5 | |
| SCHEMBL11860377 | 0.83 | KIF11 (0.49) | KIF11KLKB1SLC1A5 | |
| SCHEMBL5414771 | 0.82 | PDE4A (0.39) | — | |
| SCHEMBL3855466 | 0.81 | KIF11 (0.46) | KIF11KLKB1 | |
| SCHEMBL3855463 | 0.81 | KIF11 (0.46) | KIF11KLKB1 | |
| SCHEMBL7300113 | 0.79 | SMN1; SMN2 (0.50) | KIF11KLKB1SLC1A5 | |
| SCHEMBL11868080 | 0.79 | SMN1; SMN2 (0.50) | KIF11KLKB1SLC1A5 | |
| SCHEMBL10858055 | 0.76 | KIF11 (0.51) | KIF11KLKB1SLC1A5IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | AXYS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-6492362-B1 | Compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | CTSS, CTSB, CTSE | KIF11 4524/4885KLKB1 468/4885SLC1A5 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.